Royal Bank of Canada
LKFT

Royal Bank of Canada’s Lakefront Biotherapeutics American Depositary Shares LKFT Stock Holding History

Royal Bank of Canada’s Portfolio LKFT Stock Details LKFT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$20K Sell
672
-4,683
-87% -$155K ﹤0.01% 5897
2025
Q4 		$175K Sell
5,355
-23,074
-81% -$745K ﹤0.01% 4861
2025
Q3 		$984K Sell
28,429
-52,433
-65% -$1.68M ﹤0.01% 4003
2025
Q2 		$2.26M Buy
80,862
+79,980
+9,068% +$2.14M ﹤0.01% 3194
2025
Q1 		$23K Sell
882
-511
-37% -$12.9K ﹤0.01% 5867
2024
Q4 		$39K Buy
1,393
+320
+30% +$8.92K ﹤0.01% 5806
2024
Q3 		$31K Buy
1,073
+106
+11% +$2.89K ﹤0.01% 5906
2024
Q2 		$23K Buy
967
+54
+6% +$1.53K ﹤0.01% 6010
2024
Q1 		$29K Sell
913
-10
-1% -$372 ﹤0.01% 5756
2023
Q4 		$37K Sell
923
-1,569
-63% -$57.7K ﹤0.01% 6114
2023
Q3 		$85K Sell
2,492
-23
-0.9% -$895 ﹤0.01% 5484
2023
Q2 		$102K Buy
2,515
+24
+1% +$979 ﹤0.01% 5321
2023
Q1 		$96K Hold
2,491
– – ﹤0.01% 5210
2022
Q4 		$110K Sell
2,491
-400
-14% -$16.8K ﹤0.01% 5375
2022
Q3 		$123K Buy
2,891
+6
+0.2% +$307 ﹤0.01% 5177
2022
Q2 		$162K Sell
2,885
-212
-7% -$12.6K ﹤0.01% 4963
2022
Q1 		$192K Sell
3,097
-318
-9% -$19.5K ﹤0.01% 5125
2021
Q4 		$189K Buy
3,415
+233
+7% +$12.2K ﹤0.01% 5395
2021
Q3 		$168K Buy
3,182
+657
+26% +$39K ﹤0.01% 5322
2021
Q2 		$174K Sell
2,525
-34,920
-93% -$2.66M ﹤0.01% 5198
2021
Q1 		$2.89M Buy
37,445
+3,508
+10% +$323K ﹤0.01% 2712
2020
Q4 		$3.36M Buy
33,937
+11,262
+50% +$1.38M ﹤0.01% 2479
2020
Q3 		$3.22M Buy
22,675
+1,248
+6% +$208K ﹤0.01% 2317
2020
Q2 		$4.23M Buy
21,427
+3,181
+17% +$659K ﹤0.01% 2061
2020
Q1 		$3.58M Sell
18,246
-2,050
-10% -$441K ﹤0.01% 2047
2019
Q4 		$4.2M Buy
20,296
+1,961
+11% +$363K ﹤0.01% 2291
2019
Q3 		$2.8M Buy
18,335
+18,084
+7,205% +$2.96M ﹤0.01% 2489
2019
Q2 		$32K Buy
251
+169
+206% +$20.1K ﹤0.01% 5484
2019
Q1 		$10K Sell
82
-735
-90% -$74.1K ﹤0.01% 5978
2018
Q4 		$76K Buy
817
+757
+1,262% +$76.7K ﹤0.01% 4870
2018
Q3 		$7K Buy
60
+10
+20% +$1.06K ﹤0.01% 6112
2018
Q2 		$5K Sell
50
-899
-95% -$87.2K ﹤0.01% 6031
2018
Q1 		$95K Buy
949
+868
+1,072% +$93.6K ﹤0.01% 4724
2017
Q4 		$8K Buy
81
+31
+62% +$2.93K ﹤0.01% 5937
2017
Q3 		$5K Sell
50
-4,120
-99% -$360K ﹤0.01% 6419
2017
Q2 		$319K Buy
4,170
+2,993
+254% +$252K ﹤0.01% 4021
2017
Q1 		$101K Buy
+1,177
New +$84.8K ﹤0.01% 4756
2016
Q1 		– Sell
-420
Closed -$26K – 6464
2015
Q4 		$26K Hold
420
– – ﹤0.01% 5598
2015
Q3 		$17K Hold
420
– – ﹤0.01% 5629
2015
Q2 		$22K Buy
+420
New +$22.3K ﹤0.01% 5644

Other funds holding LKFT

GS
Gilead Sciences Foster City, California $1.65B AUM 166.99% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
MAP
Madison Avenue Partners New York $2.3B AUM 115.82% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
DCM
DME Capital Management New York $3.19B AUM 23.22% 1-Year Est. Return
SBH
Segall Bryant & Hamill Chicago, Illinois $6.98B AUM 34.78% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Royal Bank of Canada's LKFT Position: Q1 2026 in Review

Royal Bank of Canada reduced its Lakefront Biotherapeutics American Depositary Shares (LKFT) stake by 87% in Q1 2026, selling an estimated $155K and leaving 672 shares worth $20K. The position accounts for ﹤0.01% of the portfolio, ranked #5897.

Royal Bank of Canada first reported a position in LKFT in Q2 2015 and has held it in 40 quarters since. The position peaked at $4.23M in Q2 2020. 90 funds tracked by Wall St. Rank hold LKFT as of Q1 2026.

  • Royal Bank of Canada held 672 shares of Lakefront Biotherapeutics American Depositary Shares worth $20K as of Q1 2026.
  • Royal Bank of Canada sold 4,683 Lakefront Biotherapeutics American Depositary Shares shares in Q1 2026, an estimated $155K.
  • Lakefront Biotherapeutics American Depositary Shares made up ﹤0.01% of Royal Bank of Canada's portfolio in Q1 2026, its #5897 holding.
  • Royal Bank of Canada first reported a position in Lakefront Biotherapeutics American Depositary Shares in Q2 2015 and has held it in 40 quarters since.
  • Royal Bank of Canada's Lakefront Biotherapeutics American Depositary Shares position peaked at $4.23M in Q2 2020.
  • 90 funds tracked by Wall St. Rank held Lakefront Biotherapeutics American Depositary Shares as of Q1 2026.

Based on Royal Bank of Canada's 13F filing for Q1 2026, filed 15 May 2026.